How today’s life sciences manufacturers can effectively monitor processes, integrate with sub-contractors and align with regulatory reporting requirements.
Lonza exits both softgels and liquid-filled hard capsules and NextPharma plans to broaden its technology offering into lipid based finished dosage forms.
Will increase 7000L drug substance capacity (MFG21) and drug product capacity (DP11) for liquid and lyophilization within its global manufacturing network.
Tune in to this webinar for an introduction to ICP-OES and ICP-MS. Learn about their sameness and difference, along with general applications for each.
Brings in-house manufacturing capabilities for high-quality sterile antibiotic powder injectable finished dosage forms with two FDA-approved production lines.